ID   RIDA_SALTY              Reviewed;         128 AA.
AC   Q7CP78; Q7BS56;
DT   21-MAR-2012, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   07-JAN-2015, entry version 64.
DE   RecName: Full=2-iminobutanoate/2-iminopropanoate deaminase;
DE            EC=3.5.99.10;
DE   AltName: Full=Enamine/imine deaminase;
GN   Name=ridA; Synonyms=yjgF; OrderedLocusNames=STM4458;
OS   Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720).
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC   Enterobacteriaceae; Salmonella.
OX   NCBI_TaxID=99287;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION IN THE BIOSYNTHESIS OF
RP   ISOLEUCINE, AND DISRUPTION PHENOTYPE.
RC   STRAIN=LT2;
RX   PubMed=9851994;
RA   Enos-Berlage J.L., Langendorf M.J., Downs D.M.;
RT   "Complex metabolic phenotypes caused by a mutation in yjgF, encoding a
RT   member of the highly conserved YER057c/YjgF family of proteins.";
RL   J. Bacteriol. 180:6519-6528(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=LT2 / SGSC1412 / ATCC 700720;
RX   PubMed=11677609; DOI=10.1038/35101614;
RA   McClelland M., Sanderson K.E., Spieth J., Clifton S.W., Latreille P.,
RA   Courtney L., Porwollik S., Ali J., Dante M., Du F., Hou S., Layman D.,
RA   Leonard S., Nguyen C., Scott K., Holmes A., Grewal N., Mulvaney E.,
RA   Ryan E., Sun H., Florea L., Miller W., Stoneking T., Nhan M.,
RA   Waterston R., Wilson R.K.;
RT   "Complete genome sequence of Salmonella enterica serovar Typhimurium
RT   LT2.";
RL   Nature 413:852-856(2001).
RN   [3]
RP   FUNCTION IN THE BIOSYNTHESIS OF ISOLEUCINE, AND DISRUPTION PHENOTYPE.
RC   STRAIN=LT2;
RX   PubMed=18296521; DOI=10.1128/JB.01700-07;
RA   Christopherson M.R., Schmitz G.E., Downs D.M.;
RT   "YjgF is required for isoleucine biosynthesis when Salmonella enterica
RT   is grown on pyruvate medium.";
RL   J. Bacteriol. 190:3057-3062(2008).
RN   [4]
RP   DISRUPTION PHENOTYPE.
RC   STRAIN=LT2;
RX   PubMed=20817725; DOI=10.1074/jbc.M110.160515;
RA   Lambrecht J.A., Browne B.A., Downs D.M.;
RT   "Members of the YjgF/YER057c/UK114 family of proteins inhibit
RT   phosphoribosylamine synthesis in vitro.";
RL   J. Biol. Chem. 285:34401-34407(2010).
RN   [5]
RP   FUNCTION AS A DEAMINASE, BIOPHYSICOCHEMICAL PROPERTIES, MUTAGENESIS OF
RP   TYR-17; ARG-105 AND GLU-120, SUBSTRATE SPECIFICITY, AND NOMENCLATURE.
RC   STRAIN=LT2;
RX   PubMed=22094463; DOI=10.1074/jbc.M111.304477;
RA   Lambrecht J.A., Flynn J.M., Downs D.M.;
RT   "The conserved YjgF protein family deaminates enamine/imine
RT   intermediates of pyridoxal-5'-phosphate (PLP)-dependent enzyme
RT   reactions.";
RL   J. Biol. Chem. 287:3454-3461(2012).
CC   -!- FUNCTION: Accelerates the release of ammonia from reactive
CC       enamine/imine intermediates of the PLP-dependent threonine
CC       dehydratase (IlvA) in the low water environment of the cell. It
CC       catalyzes the deamination of enamine/imine intermediates to yield
CC       2-ketobutyrate and ammonia. It is required for the detoxification
CC       of reactive intermediates of IlvA due to their highly nucleophilic
CC       abilities and to avoid they are captured by anthranilate
CC       phosphoribosyltransferase (TrpD) to generate PRA, an intermediate
CC       in the alternative pyrimidine biosynthetic (APB) pathway. Also
CC       required for full activity of IlvE which is involved in the
CC       isoleucine biosynthesis. RidA also accelerates the release of
CC       pyruvate produced by IlvA from L-serine.
CC       {ECO:0000269|PubMed:18296521, ECO:0000269|PubMed:22094463,
CC       ECO:0000269|PubMed:9851994}.
CC   -!- CATALYTIC ACTIVITY: 2-iminobutanoate + H(2)O = 2-oxobutanoate +
CC       NH(3).
CC   -!- CATALYTIC ACTIVITY: 2-iminopropanoate + H(2)O = pyruvate + NH(3).
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is around 9 due to the greater stability of the
CC         enamine/imine intermediate at high pH.
CC         {ECO:0000269|PubMed:22094463};
CC   -!- PATHWAY: Amino-acid biosynthesis; L-isoleucine biosynthesis; 2-
CC       oxobutanoate from L-threonine.
CC   -!- SUBUNIT: Homotrimer. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305}.
CC   -!- DISRUPTION PHENOTYPE: Cells lacking this gene appear to be
CC       compromised in their ability to synthesize isoleucine. Mutation
CC       results in the partial block of at least one step in isoleucine
CC       biosynthesis subsequent to the reaction catalyzed by threonine
CC       deaminase (IlvA). Mutation is required for the dependence of the
CC       PurF-independent alternative pyrimidine biosynthesis (APB) pathway
CC       of thiamine upon the oxidative pentose phosphate pathway.
CC       {ECO:0000269|PubMed:18296521, ECO:0000269|PubMed:20817725,
CC       ECO:0000269|PubMed:9851994}.
CC   -!- SIMILARITY: Belongs to the RutC family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF095578; AAD22768.1; -; Genomic_DNA.
DR   EMBL; AE006468; AAL23277.1; -; Genomic_DNA.
DR   RefSeq; NP_463318.1; NC_003197.1.
DR   ProteinModelPortal; Q7CP78; -.
DR   SMR; Q7CP78; 2-128.
DR   STRING; 99287.STM4458; -.
DR   PRIDE; Q7CP78; -.
DR   EnsemblBacteria; AAL23277; AAL23277; STM4458.
DR   GeneID; 1255984; -.
DR   KEGG; stm:STM4458; -.
DR   PATRIC; 32387855; VBISalEnt20916_4691.
DR   KO; K09022; -.
DR   OMA; FFDEHNV; -.
DR   OrthoDB; EOG6QVRPF; -.
DR   PhylomeDB; Q7CP78; -.
DR   BioCyc; MetaCyc:MONOMER-18420; -.
DR   BioCyc; SENT99287:GCTI-4488-MONOMER; -.
DR   Proteomes; UP000001014; Chromosome.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0019239; F:deaminase activity; IDA:UniProtKB.
DR   GO; GO:0016787; F:hydrolase activity; IEA:UniProtKB-KW.
DR   GO; GO:0009097; P:isoleucine biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0009636; P:response to toxic substance; IEA:UniProtKB-KW.
DR   Gene3D; 3.30.1330.40; -; 1.
DR   InterPro; IPR013813; Endoribo_LPSP/chorism_mut-like.
DR   InterPro; IPR006056; YjgF-like.
DR   InterPro; IPR019897; YjgF-like_CS.
DR   InterPro; IPR006175; YjgF/Yer057p/UK114.
DR   PANTHER; PTHR11803; PTHR11803; 1.
DR   Pfam; PF01042; Ribonuc_L-PSP; 1.
DR   SUPFAM; SSF55298; SSF55298; 1.
DR   TIGRFAMs; TIGR00004; TIGR00004; 1.
DR   PROSITE; PS01094; UPF0076; 1.
PE   1: Evidence at protein level;
KW   Amino-acid biosynthesis; Branched-chain amino acid biosynthesis;
KW   Complete proteome; Cytoplasm; Detoxification; Hydrolase;
KW   Isoleucine biosynthesis; Reference proteome.
FT   CHAIN         1    128       2-iminobutanoate/2-iminopropanoate
FT                                deaminase.
FT                                /FTId=PRO_0000416001.
FT   BINDING     105    105       Substrate. {ECO:0000303|PubMed:22094463}.
FT   SITE         17     17       Stabilizes the substrate.
FT   SITE        120    120       Important for catalytic activity at high
FT                                pH.
FT   MUTAGEN      17     17       Y->F: Deaminase activity is defective. At
FT                                pH 8, strongly reduces the increase in
FT                                rate of 2-ketobutyrate formation over the
FT                                rate of IlvA alone. At pH 9.5, moderately
FT                                reduces the increase in rate of 2-
FT                                ketobutyrate formation over the rate of
FT                                IlvA alone.
FT                                {ECO:0000269|PubMed:22094463}.
FT   MUTAGEN     105    105       R->A: Deaminase activity is defective. At
FT                                pH 8 and 9.5, strongly reduces the
FT                                increase in rate of 2-ketobutyrate
FT                                formation over the rate of IlvA alone.
FT                                {ECO:0000269|PubMed:22094463}.
FT   MUTAGEN     120    120       E->A: Deaminase activity is defective. At
FT                                pH 8, moderately reduces the increase in
FT                                rate of 2-ketobutyrate formation over the
FT                                rate of IlvA alone. At pH 9.5, strongly
FT                                reduces the increase in rate of 2-
FT                                ketobutyrate formation over the rate of
FT                                IlvA alone.
FT                                {ECO:0000269|PubMed:22094463}.
FT   MUTAGEN     120    120       E->K: Deaminase activity is defective. At
FT                                pH 8, moderately reduces the increase in
FT                                rate of 2-ketobutyrate formation over the
FT                                rate of IlvA alone. At pH 9.5, strongly
FT                                reduces the increase in rate of 2-
FT                                ketobutyrate formation over the rate of
FT                                IlvA alone.
FT                                {ECO:0000269|PubMed:22094463}.
SQ   SEQUENCE   128 AA;  13576 MW;  9E66F1287DE67B1A CRC64;
     MSKTIATENA PAAIGPYVQG VDLGSMVITS GQIPVDPKTG AVAEDVSAQA RQSLENVKAI
     VEAAGLKVGD IVKTTVFVKD LNDFATVNAT YEAFFTEHNA TFPARSCVEV ARLPKDVKIE
     IEAIAVRR
//
